Arecor Therapeutics
Little Chesterford, United Kingdom

Arecor is a revenue-generating clinical-stage drug developer. Its proprietary Arestat formulation platforms are the basis of an in-house and partnered pipeline of enhanced products with lower development risks and less onerous regulatory approvals.

Investment Perspective

Momentum continues to build across Arecor’s pipeline and 2023 should see the first Arestat-based product, AT220, approved and entering a multi-billion market. Partner Hikma has confirmed it will progress AT307 through to commercialisation, with several milestones expected over the coming 18 months. Two new formulation collaborations have been signed, and one has been extended. The diabetes franchise remains in the spotlight with changing US insulin market dynamics. Insulins AT278 (ultra-concentrated, ultra-rapid) and AT247 (ultra-rapid, pump-optimised) have highly promising profiles that should be ideally placed for emerging diabetes needs. AT278 is in a second Phase I trial, with key data expected in Q423. Arecor’s formulation expertise underpins both the in-house clinical pipeline and the partnered Specialty Hospital Products programmes. Our updated valuation is £176m, or 575p per share.

Market information

SymbolPrimary exchanges


Continued delivery with key AT278 data due in Q423
Update | 20 Apr 2023
Hikma licence milestone achieved
Update | 13 Jan 2023
Getting the chemistry right
Outlook | 20 Dec 2022

Recent News

Tetris Pharma launches Ogluo in Denmark & Norway
15 May 2023
US patent grant protecting proprietary mAb formulations
26 Apr 2023
Unaudited preliminary FY22 results
20 Apr 2023
Appointment of Chief Business Officer
05 Apr 2023